BodyTel Announces 2008 Production Estimates for Bluetooth Blood Sugar
Meter At Medica Press Conference
HENDERSON, Nev., Nov. 15, 2007 (PRIME NEWSWIRE) -- BodyTel
Scientific, Inc. (OTCBB:BDYT), a developer of wireless telemedical
measuring devices, announced that it has set the initial production
number of its blood glucose meter, GlucoTel, to 350,000 units for
calendar year 2008. The units are expected to be available in
countries requiring the CE approval during the first quarter 2008 and
are expected to be on sale in countries requiring FDA certification
during the second quarter of 2008. In anticipation of the market
launch, BodyTel has submitted design and utility patents for the
worldwide intellectual property protection of GlucoTel.
In order to meet the production demand, BodyTel has formed strategic
relationships with established suppliers and manufacturers of blood
glucose meters for the serial production of the units. The final
assembly of the meter and most of the fabrication will take place in
Germany. Test strip production has been allotted to cover 10 times
the quantity of the estimated 2008 production number to offset any
potential production bottle necks. The product package will consist
of twelve components including the GlucoTel meter, strip box, lancing
device, lancets, and control solution.
"For almost two years, we have worked with the aim to start serial
production of GlucoTel and we are proud to have reached this
milestone," says Stefan Schraps, CEO of BodyTel. "The production
target of 350,000 units is our clear statement to future GlucoTel
customers, production partners and distributors. We have already
agreed on letter contracts with distributors in several countries, as
well as with health organizations in the USA. These agreed-on
purchase quantities are the calculation basis for the production
quantities of the 350,000 units."
The GlucoTel blood glucose meter is part of the BodyTel system, a
complete telemedical diabetes self-management system supporting
patients and doctors in the treatment of diabetes and its corollary
illnesses. GlucoTel electronically measures the blood sugar level and
then sends it via Bluetooth to the patient's mobile phone. After
that, the data is automatically processed to an internet database via
internet connection or SMS. The information is stored long-term.
BodyTel Scientific Inc. is a German-American telehealth company that
specializes in telemedical monitoring and management systems for
chronic diseases. The company combines its know-how in
telecommunications, internet and medical technology/diagnostics to
create new products and services for the changing needs of global
health. BodyTel products are designed not only to simplify home
monitoring by patients, but also to ease the communication of
'measured body values' to healthcare professionals or other
caregivers by bridging the gap between the patient and the caregivers
instantaneously and real-time. BodyTel's products -- GlucoTel,
PressureTel and WeightTel are each at different stages of development
and approval processes. Further information can be found at
www.bodytel.com.
Forward-Looking Statements
Statements regarding the Company's business which are not historical
facts are "forward-looking statements" that involve risks and
uncertainties that could cause actual results to differ materially
from the potential results discussed in the forward-looking
statements. Forward-looking statements in this press release include
that announced that it has set the initial production number of its
blood glucose meter, GlucoTel, to 350,000 units for calendar year
2008. The units are expected to be available in countries requiring
the CE approval during the first quarter 2008 and are expected to be
on sale in countries requiring FDA certification during the second
quarter of 2008. In anticipation of the market launch, BodyTel has
submitted design and utility patents for the worldwide intellectual
property protection of GlucoTel. Actual results may differ materially
from those currently anticipated due to a number of factors as we may
find that our products must compete with cheaper or better products;
we may not be able to retain key employees; a bigger market may not
develop for our products and we may not be able to continue to
attract new customers; we may face litigation if our technology fails
to work when required; our intellectual property may be attacked and
defeated in court proceedings; our patent and FDA/CE filings may be
rejected by the patent offices and regulators; other companies may
discover and develop better or cheaper technologies that would render
our products obsolete and we may not have sufficient funding to
further develop and/or market our technology. Readers are directed to
the BodyTel Scientific, Inc.'s reports as filed with the U.S.
Securities and Exchange Commission from time to time, including but
not limited to its 8-K filed December 14, 2006 under our prior name
Sellcell.net which outlined the company's current business for
further information and factors that may affect BodyTel Scientific
Inc.'s business and results of operations as well as the Company's
form 10-KSB filed on December 15, 2006 and the Company's form 10-QSB
filed on January 16, 2007. BodyTel Scientific Inc. undertakes no
obligations to publicly update any forward-looking statements to
reflect future events or circumstances.
CONTACT: ZA Consulting Inc.
Investors Relations
David Zazoff
212-505-5976
BodyTel Scientific, Inc.
Press Contact
Michaela Klinger
+49 (0)5621 96776 11
press@bodytel.com
www.bodytel.com
Schlachthofstr. 1
34537 Bad Wildungen
Germany
Torsten Herrmann
06192/96 166 80
therrmann@chainrelations.de
www.chainrelations.de
Wilhelmstrasse 37
65719 Hofheim
Germany
